Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01326364
First received: April 14, 2010
Last updated: June 30, 2016
Last verified: June 2016

April 14, 2010
June 30, 2016
March 2010
June 2012   (final data collection date for primary outcome measure)
  • Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level) [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01326364 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
pancreatic adenocarcinoma
Pancreatic Cancer
  • Procedure: Stereotactic body radiotherapy
    Standard of Care
    Other Name: CyberKnife
  • Drug: Iodixanol
    IV, calculated per patient
    Other Name: Visipaque
  • Drug: Iohexol
    IV, Calculated per patient
    Other Name: Omnipaque
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
6
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and
  2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria:

1) are absolute contraindications to intravenous iodinated contrast or CT scan.

Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01326364
PANC0009, SU-03182010-5282
Yes
Not Provided
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Aya Kamaya Stanford University
Stanford University
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP